337 related articles for article (PubMed ID: 9776319)
1. Interaction of cyclic GMP and cyclic AMP during neutrophil migration: involvement of phosphodiesterase type III.
VanUffelen BE; de Koster BM; Elferink JG
Biochem Pharmacol; 1998 Oct; 56(8):1061-3. PubMed ID: 9776319
[TBL] [Abstract][Full Text] [Related]
2. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
3. Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes.
Weiss HR; Lazar MJ; Punjabi K; Tse J; Scholz PM
Eur J Pharmacol; 2003 Nov; 481(1):25-31. PubMed ID: 14637171
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
5. Cyclic nucleotide-induced migration of electropermeabilized neutrophils: the effect of phosphodiesterase-resistant analogues.
VanUffelen BE; de Koster BM; VanSteveninck J; Elferink JG
Inflamm Res; 1997 Oct; 46(10):427-9. PubMed ID: 9372318
[TBL] [Abstract][Full Text] [Related]
6. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
7. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
8. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells.
Yao J; Hiramatsu N; Zhu Y; Morioka T; Takeda M; Oite T; Kitamura M
J Am Soc Nephrol; 2005 Jan; 16(1):58-67. PubMed ID: 15537869
[TBL] [Abstract][Full Text] [Related]
10. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors.
Palmer D; Tsoi K; Maurice DH
Circ Res; 1998 May; 82(8):852-61. PubMed ID: 9576105
[TBL] [Abstract][Full Text] [Related]
13. The effect of phosphodiesterase III inhibitors on human neutrophil function.
Mikawa K; Akamatsu H; Nishina K; Shiga M; Maekawa N; Obara H; Niwa Y
Crit Care Med; 2000 Apr; 28(4):1001-5. PubMed ID: 10809273
[TBL] [Abstract][Full Text] [Related]
14. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Zhao H; Quilley J; Montrose DC; Rajagopalan S; Guan Q; Smith CJ
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2973-81. PubMed ID: 17293498
[TBL] [Abstract][Full Text] [Related]
16. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
17. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
18. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
19. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
20. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
